FGF-1 for Topical Administration for the Treatment of Diabetic or Venous Stasis Ulcers

StatusCompleted
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 2 versions Re-verified since Oct 31, 2019, no change to tracked fieldsv7-v8
  2. Primary completion date: Sep 2, 2006
    • Study completion date: Dec 1, 2006
    • Start date: Sep 2005 to Sep 2, 2005
    • Collaborators expanded, about 3 words
    v6
  3. Eligibility criteria revisedv5
  4. Trial status: Recruiting to Completed
    • Site details revised
    v4
  5. Study sites: 2 to 1v3
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
FGF-1 is being used for the treatment of patients with diabetic or venous stasis ulcers. Procedure includes topical administration of FGF-1 or placebo and evaluation of safety, pharmacokinetics, and wound improvement.
Trial Details
NCT Number NCT00425178
Lead Sponsor Venturis Therapeutics, Inc.
Collaborators: Warren General Hospital
Conditions
(from sponsor)		 Chronic Wounds, Diabetes, Venous Stasis Ulcers
Related terms Diabetes Mellitus, Ulcer, Varicose Ulcer
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov